1. Introduction {#s0005}
===============

Chronic Kidney Disease (CKD) is a global public health problem reaching high prevalence and demanding elevated health costs. It is characterized by a slow, progressive and irreversible decline of renal function; it is usually asymptomatic and thus untreated [@bb0005]. National Kidney Foundation guidelines classify the severity of Chronic Kidney Disease in five stages. Stage 5 CKD is often called End Stage Renal Disease (ESRD) and is characterized by severe illness with poor life expectancy if untreated. However, ESRD is a complex disorder with a variety of phenotypes emanating from a variety of underlying kidney disorders in conjunction with genetic and environmental factors as well as other preexisting or secondary clinical entities [@bb0010]. Treatment in ESRD is renal replacement which encounters dialysis or kidney transplantation [@bb0015]. Persons at high risk predominantly suffer from diabetes mellitus or hypertension [@bb0020]. Nevertheless, many common adult-onset kidney disorders may be due to various risk-alleles and to interactions between various genes and gene--environment interactions [@bb0025].

Immunoglobulin A Nephropathy (IgAN), where IgA deposits are found in the glomerular mesangial area, is the most common form of glomerulonephritis world-wide and leads to ESRD in about 20% of the cases [@bb0030; @bb0035]. Vesicoureteral Reflux (VUR) is a form of Congenital Anomaly of the Kidney and Urinary Tract (CACUT) [@bb0040]. It is a very common urological cause of renal insufficiency in children, culminating to ESRD in children, adolescents, and young adults, which is potentially preventable [@bb0045].

The Renin--Angiotensin System (RAS) influences sodium balance, extracellular fluid (ECF) volume, and renal and systemic vascular resistance. Thus, the RAS serves as one of the most powerful regulators of arterial blood pressure [@bb0050]. The primary effector molecule of this system is angiotensin II (ANG II) and is formed after two cleavage steps by Renin and Angiotensin Converting Enzyme (ACE). The ANG II mediates its actions via two G protein-coupled receptors, the Angiotensin II type 1 Receptor (AGTR1) and Angiotensin II type 2 Receptor (AGTR2) [@bb0050; @bb0055].

ANG II binds to AGTR1 and induces systemic vasoconstriction, a situation that leads to elevated peripheral resistance, and ultimately increases blood pressure. Arterial hypertension (HT) is frequently associated with chronic renal failure, and it is the most important risk factor for the progression of renal failure. In summary, RAS proteins convey the response of the kidneys to effective circulating volume thus regulating salt and water handling by the kidney. This fine-tuned molecular balance may be adversely influenced by a genetically mediated variability of RAS protein variants, leading to early damage of the cardiovascular or renal organ systems [@bb0050].

Although yet quite complex, there is strong evidence of genetic susceptibility in renal failure [@bb0025; @bb0050; @bb0060]. In the present study, we attempted to clarify the genetic association of polymorphisms of the angiotensin receptors with renal diseases and discus the possibility that these polymorphisms may be used as prognostic markers for renal failure.

2. Materials and methods {#s0010}
========================

2.1. Literature search {#s0025}
----------------------

A comprehensive literature search until November 2012 was performed and 30 independent studies were retrieved that could fulfill all the eligible criteria. The keywords that were used for the search were: AGTR, AGTR1, AGTR1B, AGTR2, 'ANGIOTENSIN RECEPTOR', 'ANGIOTENSIN II RECEPTOR', GENE, VARIANT, POLYMORPHISM, MUTANT, MUTATION, ALLELE, 'CHRONIC KIDNEY DISEASE', 'KIDNEY FAILURE' 'END-STAGE KIDNEY DISEASE', 'END-STAGE RENAL DISEASE', 'END-STAGE RENAL FAILURE', DIALYSIS, 'IgA GLOMERULONEPHRITIS', 'IgA NEPHROPATHY', 'VESICOURETERAL REFLUX', VUR and combinations of them. To enrich the investigation, references of published studies were incorporated.

2.2. Data extraction {#s0030}
--------------------

Data extraction from each study was performed by two reviewers according to the eligibility criteria. All problems of poor agreement, when they occurred, were resolved after discussion with a third investigator and the necessary data were stratified in spreadsheet. The following data were extracted from each study: Pubmed ID, first author\'s name, year of publication, geographical location and ethnicity of population studied, and total number of the subjects (cases and control groups). The distributions of alleles and genotypes were calculated in cases and controls for each study and are shown in Tables S1--S5. When a case--control study was designed according to a family based model, the family-trio model was encountered that distinguishes between affected offspring and non-affected parents (controls) and analysis was performed according to the transmission disequilibrium test (TDT) [@bb0065].

2.3. Statistical analysis {#s0035}
-------------------------

Odds ratio (OR) was used as the effect size of choice to test the association between the mutant alleles or genotypes (as defined in each polymorphism case), and the disease phenotypes. In case of a zero cell, a continuity correction was applied by adding 0.5 to all cells of the contingency table. Data were combined using a random-effects method [@bb0070] with inverse-variance weights, and ORs were calculated along with their 95% CIs for each genotype or allele contrast. The between study heterogeneity was evaluated using the chi-square based Cochran\'s Q statistic and the consistency index (I^2^) [@bb0075].

The multivariate random-effects method of meta-analysis was also applied as a more advanced method for testing gene--disease associations. In this framework, the two summary log-odds ratios related to the risk allele, e.g. the log-odds ratio of heterozygotes vs. homozygotes (AB vs. AA) and the log-odds ratio of homozygotes for the risk allele vs. homozygotes for the wild type allele (BB vs. AA), are modeled simultaneously as a bivariate response. This method has several important properties, since it can infer and quantify the genetic model of inheritance directly, by estimating the ratio λ of the two log-odds ratios [@bb0080; @bb0085; @bb0090; @bb0095]. This way, we avoid multiple testing and thus the inflation of the Type I error rate. Stata 10 (StataCorp) was the statistical package that was used for all the analyses. Results with p-value \< 0.05 were considered statistically significant.

To estimate possible publication bias, the rank correlation method of Begg and Mazumdar [@bb0100] was used. Additionally, the fixed effects regression method of Egger was also recruited [@bb0105]. Influential meta-analysis was further performed, by removing an individual study each time, and re-calculating the effects estimates (ORs) and heterogeneity. In order to identify a possible trend of the combined estimate over years, a condition that often introduces a special kind of bias ("Proteus phenomenon"), cumulative meta-analysis was also performed. Time-trend was detected using two methods: the standard cumulative meta-analysis [@bb0110; @bb0115; @bb0120] approach, where we visually inspect the plot, and a more recently proposed regression-based method [@bb0125].

3. Results {#s0015}
==========

A literature search was performed to identify all studies assessing the association of *Angiotensin II type 1 Receptor* (*AGTR1*) and *Angiotensin II type 2 Receptor* (*AGTR2*) gene polymorphisms with renal diseases. Meta-analyses were performed for the polymorphisms for which at least three studies were found. Polymorphisms of both genes related to disease phenotypes along with the number of studies identified and numbers of patients and controls included in each meta-analysis are shown in [Table 1](#t0005){ref-type="table"}.

3.1. A1166C polymorphism of AGTR1 gene {#s0040}
--------------------------------------

In a meta-analysis to test the putative association of the A1166C (rs5186) polymorphism of the *AGTR1* gene with ESRD 109 studies were retrieved. Nevertheless, only 17 studies were included [@bb0130; @bb0135; @bb0140; @bb0145; @bb0150; @bb0155; @bb0160; @bb0165; @bb0170; @bb0175; @bb0180; @bb0185; @bb0190; @bb0195; @bb0200; @bb0205; @bb0210] that fulfilled the selection criteria and comprised of 2596 patients and 3866 controls. One study [@bb0160] had a family based design, (trio), and it was analyzed with the transmission disequilibrium test (TDT) according to the method presented in [@bb0065].

The characteristics of each study are shown in [Table 2A](#t0010){ref-type="table"}, while details about alleles and genotypes are shown in Table S1. No statistical significant association was found for the per-allele contrast since OR was 1.10 with 95% CI: 0.91--1.34. Similarly, non-significant association was found when dominant and recessive models were analyzed (CC + AC vs AA: OR 1.15, 95% CI: 0.92--1.44 and CC vs AA + AC: OR 1.31, 95% CI: 0.83--2.07, [Table 3](#t0035){ref-type="table"}). Meta-analysis in subgroups according to race did not yield any significant association (data not shown). Similarly, when meta-analysis was restricted to studies in Hardy--Weinberg Equilibrium (HWE) no significant associations were found (data not shown).

In all three meta-analyses heterogeneity was high since p-value \< 0.05 and I^2^ \> 50% ([Table 3](#t0035){ref-type="table"}), while no publication bias was observed (p-value \> 0.05 for all tests). Furthermore, Proteus phenomenon was not detected in cumulative meta-analysis for the ΑΑ vs AC + CC contrast, while for the A vs C and the CC vs AA + AC contrasts a time trend was obvious ([Table 4](#t0040){ref-type="table"}). Influential meta-analysis was also performed and showed that no individual study influenced the effect estimate (data not shown).

After that, a meta-analysis was carried out to test the association of the same polymorphism (*AGTR1* A1166C) with Chronic Kidney Disease (CKD). From the 109 studies only eight were found eligible to provide data for 812 patients and 4252 healthy subjects [@bb0180; @bb0185; @bb0190; @bb0200; @bb0210; @bb0220; @bb0225; @bb0230]. The characteristics of all studies are shown in [Table 2B](#t0015){ref-type="table"} and numbers of alleles and genotypes in Table S2.

Association of CKD and A1166C polymorphism of *AGTR1* gene could not be found neither with per allele contrast nor with genotype contrasts. The ORs were 1.16 (95% CI: 0.83--1.64) for the per allele contrast (C vs A), 1.06 (95% CI: 0.50--2.25) for the CC vs AA + AC contrast and 1.16 (95% CI: 0.82--1.63) for the CC + AC vs AA contrast. Excluding one study of which the population was not in HWE did not grant significance to the association (data not shown). Heterogeneity was rather low in all cases with p-values \> 0.05 and I^2^ \< 50% ([Table 3](#t0035){ref-type="table"}), with no publication bias (p-value \> 0.05 for all tests, data not shown). No time trend was observed in any of the contrasts ([Table 4](#t0040){ref-type="table"}). No individual study was found to influence the effect estimate of the remaining of the studies at an influential meta-analysis (data not shown).

Afterwards, IgA Nephropathy was investigated for its association with the A1166C polymorphism of the *AGTR1*. 36 studies were found from the literature search, however, only five fulfilled all the appropriate criteria and were used in the meta-analysis [@bb0155; @bb0185; @bb0190; @bb0235; @bb0240]. In total, they contained 785 patients and 1373 controls ([Tables 2C](#t0020){ref-type="table"} and S3) and all populations were in HWE. Meta-analysis for the allele contrast (C vs A) produced an OR of 1.00 (95% CI: 0.84--1.17) indicating the absence of any association of the A1166C polymorphism with IgA Nephropathy. Likewise, no association was found in the other two genotype contrasts (CC vs AA + AC and CC + AC vs AA) as shown in [Table 3](#t0035){ref-type="table"}. Heterogeneity was very low in all contrasts with p-values \> 0.05 and I^2^ \< 50% ([Table 3](#t0035){ref-type="table"}) and no publication bias (p-value \> 0.05 for all tests, data not shown) was observed. Proteus phenomenon was observed in the C vs A and the CC + AC vs AA contrast while in the CC vs AA + AC contrast no time trend was observed ([Table 4](#t0040){ref-type="table"}). According to the influential meta-analysis performed, there was no study to influence the ORs of the remaining studies (data not shown).

Subsequently, we wished to analyze the association of A1166C polymorphism of *AGTR1* gene with Vesicoureteral Reflux (VUR). From the literature search 14 studies were initially retrieved, but only three could be used in the meta-analyses [@bb0200; @bb0245; @bb0250; @bb0255]. Altogether they included 174 patients and 216 healthy controls ([Tables 2D](#t0025){ref-type="table"} and S4). However, the study of Liu and coworkers [@bb0200] could be used only for allele contrasts since no genotype data was presented. As shown in [Table 3](#t0035){ref-type="table"}, meta-analysis under the C vs A allele contrast illustrated an OR 1.07 (95% CI: 0.68--1.67) suggesting no statistical significant association. Likewise, the genotype contrasts did not give any evidence for a significant association of *AGTR1* A1166C polymorphism with VUR ([Table 3](#t0035){ref-type="table"}).

Between study heterogeneity was very low in all contrasts since p-values \> 0.05 and I^2^ \< 50% ([Table 3](#t0035){ref-type="table"}). No publication bias was observed with p-value \> 0.05 for all tests (data not shown). Time trend was observed (Proteus phenomenon) for the C vs A contrast ([Table 4](#t0040){ref-type="table"}), while for the other two contrasts calculations could not be performed since only two studies were included. In an influential meta-analysis no individual study was found to influence the ORs of the rest (data not shown).

3.2. A1332G polymorphism of AGTR2 gene {#s0045}
--------------------------------------

Finally, another polymorphism, A1332G of the *AGTR2* gene was also analyzed for its association with VUR. Initially 14 studies were retrieved from the literature search, yet, only three abided with the selection criteria and were used in the meta-analysis [@bb0250; @bb0260; @bb0265]. Altogether, they comprised 352 patients, 790 controls. All studies included Caucasian populations ([Tables 2E](#t0030){ref-type="table"} and S5). Because *AGTR2* gene is on X chromosome, one study [@bb0265] gave data for males and females separately, and thus two cohorts were included in the initial meta-analysis. One study [@bb0250] presented data only for males, and data from [@bb0260] was on mixed population. Meta-analysis for the allele contrast on mixed populations revealed no association of *AGTR2* A1332G polymorphism since OR was 1.13 with 96% CI 0.66--1.92. No publication bias was observed (p-value \> 0.05 for all tests, data not shown) and significant heterogeneity appeared (p-value 0.041 and I^2^ = 63.8%, [Table 3](#t0035){ref-type="table"}). Time trend (Proteus phenomenon) was also observed ([Table 4](#t0040){ref-type="table"}). Meta-analysis for male populations was additionally carried out, but did not present any significant association ([Table 3](#t0035){ref-type="table"}). Thus, association of *AGTR2* A1332G polymorphism in males with VUR could not be proven ([Table 3](#t0035){ref-type="table"}).

3.3. ΑGTR1 Α1166C and hypertension in ESRD patients {#s0050}
---------------------------------------------------

From the 17 studies we recruited in the meta-analysis for the association of *ΑGTR1* Α1166C with ESRD, three of them were found to test the influence of the variant on hypertension development in patients with ESRD [@bb0140; @bb0195; @bb0210]. Data was given only for the ΑΑ vs CC + AC contrast and thus we were able to perform a meta-analysis concerning this contrast. The OR was found equal to 0.98 with 95% CI: 0.68, 1.42 suggesting no association of A1166C polymorphism with hypertension in ESRD patients. According to Begg and Egger tests there was no publication bias and heterogeneity was very low (data not shown).

3.4. Multivariate meta-analyses for the association of AGTR1 A1166G polymorphism with renal disease phenotypes {#s0055}
--------------------------------------------------------------------------------------------------------------

To validate the above results, multivariate meta-analyses were performed. The analysis that was performed revealed no evidence for the association of AGTR1 A1166C polymorphism with ESRD, since the ΑC vs AA yields a p-value = 0.181 and OR: 1.14 (95% CI: 0.94, 1.37) and the CC vs AA, an OR: 1.29 (95% CI: 0.78, 2.15) and p-value = 0.319 ([Table 5](#t0045){ref-type="table"}). Likewise, multivariate meta-analysis did not detect any significance for the association of this polymorphism with CKD. No association of AGTR1 A1166C polymorphism with IgA Nephropathy could be proven since the ORs were 1.01 (95% CI: 0.81, 1.25) and 0.95 (95% CI: 0.61, 1.47) for the AC vs AA and CC vs AA contrasts respectively. Similarly, multivariate meta-analysis suggested no significant association with VUR for either dominant ΑC vs AA \[OR: 1.29 (95% CI: 0.73, 2.29)\] or the recessive contrast \[CC vs AA \[OR: 0.16 (95% CI: 0.02, 1.39)\]\] ([Table 5](#t0045){ref-type="table"}). Nevertheless, these findings were expected since the majority of the univariate tests were unable to show an association. Multivariate meta-analysis could help in avoiding an inflation of the Type I error rate (i.e. reduce false positive findings), but it does not offer greater statistical power.

4. Discussion {#s0020}
=============

The Renin--Angiotensin System plays a pivotal role in the physiology of the kidneys. In non-dialyzed CKD patients, ACE inhibitors and AGTR blockers are used as the treatment of choice since they grant greater survival [@bb0050; @bb0270]. It has been recently shown [@bb0275] that *AGT* M235T gene polymorphism is associated with ESRD susceptibility in Caucasians. In addition, a meta-analysis [@bb0280] demonstrated genetic association of *ACE* I/D polymorphism with ESRD risk which actually correlates well with findings that increased circulating ACE levels in plasma are related with *ACE* I/D polymorphism [@bb0285].

Both A1166C of *AGTR1* and A1332G of *AGTR2* are within the 3′ untranslated regions of the genes. Though these polymorphisms do not lead to amino acid substitutions, these 3′ untranslated regions may play a pivotal role in the genomic context of the genes and may influence their expression levels, since they could result in defects in messenger RNA (mRNA) processing, mRNA half-life, or affect the function of regulatory elements such enhancers and insulators [@bb0010; @bb0290]. The deletion/insertion polymorphism in intron 16 of the ACE gene is an example of such non-coding sequence polymorphisms that influence gene function. Moreover, Sethupathy et al. [@bb0295] have shown that there is a miRNA from chromosome 21, namely miR155, that downregulates the expression of the 1166A allele but not of the 1166C. They hypothesize that the 1166C allele is associated with hypertension just because miR155 cannot negatively control the expression levels of AGTR1.

In view of the above data, considering the fact that AGT, ACE and AGTRs perform in the same biochemical pathways, and taken the number of case--control studies investigating relationship of *AGT receptors* gene variants with kidney diseases, in the present meta-analysis we set out to explore putative genetic associations of *AGTR1* and *AGTR2* gene polymorphisms with renal diseases. We investigated these associations for sub-group renal diseases such as ESRD, CKD, IgA Nephropathy and VUR.

Though very promising, and despite the inclusion of 2596 patients and 3866 healthy controls from 17 studies, no statistical significant association of *AGTR1* A1166C polymorphism with ESRD was found either in the allele contrasts or in the dominant and recessive models. Subgroup analysis by ethnicity or by studies in HWE did not change this pattern of results. The main analysis revealed significant heterogeneity under the allele contrast, the recessive and dominant models, implying that these results may not change even in a future meta-analysis that would contain additional studies. This is further corroborated by our findings showing that contrasts for the allele, recessive and dominant models needed two to three times more subjects to obtain significant results (data not shown) according to calculations based on the Barrowman et al. method [@bb0300]. Multivariate meta-analysis did not change the significance of the results. Thus no significant association of *AGTR1* A1166C polymorphism with ESRD was proven.

Similarly, meta-analyses revealed lack of association of *AGTR1* A1166C polymorphism with CKD and non-significant heterogeneity under the allele contrast, the recessive and dominant models. This pattern did not change under subgroup analysis by race and by HWE, neither did it change when multivariate meta-analysis was performed. Time--trend related bias (Proteus phenomenon) was not detected reinforcing the absence of association of *AGTR1* A1166C with CKD. Besides, due to low heterogeneity and according to our calculation (needing four to 1500 times more subjects to reach significance) based on the Barrowman et al. method [@bb0300], we believe that the absence of association of *AGTR1* A1166C polymorphism with CKD is rather factual.

Similarly, no association was found between *AGTR1* A1166C polymorphism and IgA Nephropathy and VUR, under all contrasts (allele and genotypes) tested. While for the association with IgAN the absence of association was pretty clear, the ORs for the association with VUR were fluctuating between various contrasts, due to the very small number of studies (three for allele contrast and two for the genotypes contrasts). Further evaluations suggested very low heterogeneity of the studies and no publication bias. Time--trend related bias (Proteus phenomenon) detected in these meta-analyses denote that more studies will improve the significance of our results. Additional multivariate meta-analyses that we performed confirmed the lack of association of *AGTR1* A1166C polymorphism with IgAN and VUR.

Furthermore, we attempted to investigate the involvement of the A1332G polymorphism of the *AGTR2* gene, located in the X chromosome, in the pathogenesis of VUR. Meta-analysis of the available data from three studies including both male and female populations showed no association under the allele contrast.

It should be mentioned that the absence of any association of the two aforementioned polymorphisms was relatively unexpected, considering the fact that polymorphisms of the other two RAS proteins genes (*AGT* and *ACE*) do associate with renal diseases. Nevertheless, no Genome Wide Association Study (GWAS) revealed *AGTR*s polymorphisms as putative markers for renal disease progression. However, these findings did not discourage our study because GWASs do have some limitations since they often explain only a few percent of the variance of the phenotype, and it is difficult to assign mechanistically the loss of function of a specific gene to one polymorphism [@bb0025; @bb0305]. In support of our first idea of *AGTR* association with renal diseases is the fact that the *AGT* M235T and *AGTR1* A1166C polymorphisms have been associated with diabetic nephropathy in a meta-analysis [@bb0310], but not with diabetes (to the best of our knowledge). On the other hand, and in support of our results, a publication came during the preparation of the present manuscript showing lack of association of *AGTR1* A1166C polymorphism with the risk for ESRD [@bb0315], though including only eight studies as compared to 17 that we included in the present study. Taken together our data suggest that neither *AGTR1* A1166C nor *AGTR2* A1332G polymorphisms can be used as reliable markers to predict the risk for CKD, ESRD, IgAN or VUR.

Appendix A. Supplementary data {#s0060}
==============================

Supplementary material.

We thank Dr. Vaios Papadimitriou for the discussions and critical reading of the manuscript.

###### 

Polymorphisms of *AGTR1* and *AGTR2* genes studied for their association with renal diseases.

  Disease   Gene    SNP             Patients/controls   Number of studies
  --------- ------- --------------- ------------------- -------------------
  ESRD      AGTR1   A1166C/rs5186   2596/3866           17
  ESRD      AGTR1   C521T                               1
  ESRD      AGTR1   A1138T                              1
  ESRD      AGTR1   AG214CC                             1
  CKD       AGTR1   A1166C/rs5186   812/4252            8
  CKD       AGTR1   C573T                               1
  CKD       AGTR1   C521T                               2
  CKD       AGTR1   A1138T                              1
  CKD       AGTR1   AG214CC                             1
  CKD       AGTR1   G163A                               2
  CKD       AGTR2   A1332G/rs5194                       1
  IgAN      AGTR1   A1166C/rs5186   785/1373            5
  VUR       AGTR1   A1166C/rs5186   174/216             3
  VUR       AGTR2   A1332G/rs5194   352/790             3

###### 

Characteristics of studies included in the meta-analysis for the association of *AGTR1* A1166C polymorphism with ESRD.

  Study           Year   Country     Race         Cases   Diagnostic criteria                                                                     Controls   Diagnostic criteria
  --------------- ------ ----------- ------------ ------- --------------------------------------------------------------------------------------- ---------- ----------------------------------------------------------------------------------------------------------------------
  Zsom M          2011   Hungary     Caucasian    134     ESRD with primary glomerulonephritis interstitial nephritis, hypertension related CKD   200        Healthy and age-matched controls
  Elshamaa MF     2011   Egypt       Other        44      Pediatric patients with ESRD based on e GFR on MHD                                      70         Healthy control subjects with no clinical signs of vascular or renal disease and no family history
  Huang HD        2010   China       Asian        47      ESRD patients a) mainly on MHD, b) transplant recipients c) IgA Nephropathy             120        Healthy subjects
  Ayed Kh         2006   Tunisia     African      131     Renal transplant recipients                                                             50         Normotensive healthy subjects with clear yearly examinations and negative hypertension history
  Tabel Y         2005   Turkey      Other        13      Children with end-stage renal insufficiency                                             287        Healthy adult subjects
  Buraczynska M   2006   Poland      Caucasians   745     Hemodialysis (n = 687) and peritoneal dialysis (n = 58) patients                        520        Healthy control subjects with no clinical signs of vascular or renal disease and no family history of renal disease
  Lau YK          2004   Singapore   Asian        32      Biopsy-proven primary IgAN-ESRD on MHD                                                  94         Healthy subjects
  Liu KP          2004   Taiwan      Asian        16      Children with VUR progressing to ESRD                                                   117        Unrelated healthy adults without renal disease
  Lee KB          2003   Korea       Asian        24      ADPKD-ESRD patients                                                                     105        Normotensive controls
  Coll E          2003   Spain       Caucasian    104     Dialysis patients                                                                       131        Healthy subjects with absence of nephropathy, renal failure, diabetes mellitus, or cardiovascular diseases
  Papp F          2003   Hungary     Caucasian    70      ESRD patients (20 pediatric, 50 adult)                                                  150        Normotensive healthy subjects (130 adults, 20 children)
  Losito A        2002   Italy       Caucasian    160     Hemodialysis patients                                                                   169        Healthy blood donors and hospital staff
  Buraczynska M   2002   Poland      Caucasian    430     Hemodialysis (n = 407) and peritoneal dialysis (n = 23) patients                        260        Healthy control subjects, with no clinical signs of vascular or renal disease and no family history of renal disease
  Basset el-EA    2002   France      Caucasian    294     Transplant recipients                                                                   181        Gender matched normal local subjects
  Filler G        2001   Germany     Caucasian    100     Pediatric transplant recipients                                                         100        Healthy consecutive newborns
  Frimat L        2000   France      Caucasian    76      IgA-ESRD patients                                                                       960        Healthy Caucasian men in the Stanislas cohort
  Gumprecht J     2000   Poland      Caucasian    176     ESRD patients                                                                           352        Not reported

MHD: hemodialysis, ADPKD: Autosomal dominant polycystic kidney disease.

###### 

Characteristics of studies included in the meta-analysis for the association of *AGTR1* A1166C polymorphism with CKD.

  Study         Year   Country     Race                Cases   Diagnostic criteria                                                                                                                                                        Controls   Diagnostic criteria
  ------------- ------ ----------- ------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- --------------------------------------------------------------------------------------------
  Su SL         2012   Taiwan      Asian               135     Patients with stages 3--5 CKD according to US National Kidney Foundation [@bb0005], modified                                                                               270        Healthy subjects age- and sex-matched
  Zsom M        2011   Hungary     Caucasian           61      CKD patients with primary glomerulonephritis, interstitial nephritis, Hypertension related CKD                                                                             200        Healthy and age-matched controls
  Elshamaa MF   2011   Egypt       Egyptian            32      Pediatric patients with advanced CKD (stage 4) based on e GFR under CT                                                                                                     70         Healthy subjects with no clinical signs of vascular or renal disease and no family history
  Huang HD      2010   China       Asian               83      IgAN non-ESRD patients                                                                                                                                                     120        Healthy subjects
  Hsu CC        2006   US          African Americans   307     CKD progression defined as a) increase in SCr ≥ 35 μmol, b) hospitalization discharge, c) death coded for chronic renal disease \[ICD-9\] codes 581 to 583 or 585 to 588   3331       Not reported
  Peruzzi L     2005   Italy       Caucasian           50      Patients with renal hypodysplasia                                                                                                                                          50         Healthy subjects matched for sex, age and origin
  Lau YK        2004   Singapore   Asian               86      Biopsy-proven primary IgAN-non-ESRD                                                                                                                                        94         Healthy subjects
  Liu KP        2004   Taiwan      Asian               58      VUR patients diagnosed by voiding cystourethroradiography and graded as I--V                                                                                               117        Unrelated healthy adult volunteers without renal disease

e GFR: estimated glomerular filtration rate, CT: conservative treatment, ICD-9: international classification of diseases, ninth revision, SCr: serum creatinine.

###### 

Characteristics of studies included in the meta-analysis for the association of *AGTR1* A1166C polymorphism with IgA Nephropathy.

  Study        Year   Country     Race        Cases   Diagnostic criteria                                                                                      Controls   Diagnostic criteria
  ------------ ------ ----------- ----------- ------- -------------------------------------------------------------------------------------------------------- ---------- ----------------------------------------------------------------------------------------
  Huang HD     2010   China       Asian       130     IgAN by renal biopsy                                                                                     120        Healthy subjects
  Lau YK       2004   Singapore   Asian       118     IgAN patients                                                                                            94         Not reported
  Maruyama K   2001   Japan       Asian       95      IgAN patients                                                                                            99         Healthy adult volunteers with no history of renal disease or abnormal urinary findings
  Frimat L     2000   France      Caucasian   274     IgAN defined as glomerulo-nephritis with predominantly IgA deposits in the mesangium of all glomeruli.   960        Healthy subjects in the Stanislas cohort
  Pei Y        1997   Canada      Caucasian   168     IgA by renal biopsy                                                                                      100        Healthy subjects with no history of renal disease or hypertension

###### 

Characteristics of studies included in the meta-analysis for the association of *AGTR1* A1166C polymorphism with VUR.

  Study            Year   Country   Race        Cases   Diagnostic criteria                                                              Controls   Diagnostic criteria
  ---------------- ------ --------- ----------- ------- -------------------------------------------------------------------------------- ---------- ----------------------------------------------------------
  Liu KP           2004   Taiwan    Asian       74      VUR diagnosed by VCUG and graded as I--V                                         117        Unrelated healthy adult volunteers without renal disease
  Haszon I         2002   Hungary   Caucasian   77      VUR graded as I--V                                                               80         Healthy blood donors
  Hohenfellner K   1999   Germany   Caucasian   23      VUR diagnosed by radiological investigations including VCUG and graded as I--V   19         boys with absence of any disorder of the urinary tract

VCUG: voiding cysto-urethrography.

###### 

Characteristics of studies included in the meta-analysis for the association of *AGTR2* A1332G polymorphism with VUR.

  Study            Year   Country   Race        Cases   Diagnostic criteria                                                                     Controls   Diagnostic criteria
  ---------------- ------ --------- ----------- ------- --------------------------------------------------------------------------------------- ---------- ----------------------------------------------------------------
  Rigoli L         2004   Italy     Caucasian   27      Primary VUR according to the International Reflux Classification [@bb0215]              92         Children with no renal disease
  Yoneda A         2002   Ireland   Caucasian   302     Male and female VUR patients from 88 families                                           679        Healthy controls, and non-affected family members
  Hohenfellner K   1999   Germany   Caucasian   23      Male VUR patients (grades I--V, according to the International Reflux Classification)   19         Healthy boys with absence of any disorder of the urinary tract

###### 

Univariate meta-analysis for all contrasts performed for both *AGTR1* (A1166C) and *AGTR2* (A1332G) polymorphisms for its association with diseases as indicated.

  SNP              Contrast   Disease      Number of studies   Odds ratio (random effects)   95% confidence interval   Cochran\'s Q   p-value for heterogeneity   I^2^ (%)   Between studies variance (τ^2^)
  ---------------- ---------- ------------ ------------------- ----------------------------- ------------------------- -------------- --------------------------- ---------- ---------------------------------
  A1166C/*AGTR1*   A vs C     ESRD         16                  1.10                          0.91  1.34                53.06          0.000                       71.7%      0.097
  CKD              7          1.16         0.83  1.64          10.41                         0.109                     42.3%          0.087                                  
  IgAN             5          0.99         0.84  1.17          2.31                          0.678                     0.0%           0.000                                  
  VUR              3          1.07         0.68  1.67          2.29                          0.318                     12.8%          0.022                                  
  CC vs AA + AC    ESRD       14           1.31                0.83  2.07                    30.80                     0.004          57.8%                       0.370      
  CKD              6          1.06         0.50  2.25          3.16                          0.675                     0.0%           0.000                                  
  IgAN             5          0.94         0.62  1.45          0.51                          0.973                     0.0%           0.000                                  
  VUR              2          0.14         0.02  1.22          0.10                          0.749                     0.0%           0.000                                  
  CC + AC vs AA    ESRD       15           1.15                0.92  1.44                    38.42                     0.000          63.6%                       0.108      
  CKD              7          1.16         0.82  1.63          11.03                         0.087                     45.6%          0.091                                  
  IgAN             5          1.00         0.81  1.23          3.05                          0.550                     0.0%           0.000                                  
  VUR              2          1.15         0.66  2.01          0.36                          0.551                     0.0%           0.000                                  
  A1332G/*AGTR2*   A vs C     VUR          4 (mixed)           1.13                          0.66  1.92                8.28           0.041                       63.8%      0.649
  2 (males)        0.67       0.41  1.10   0.61                0.433                         0.0%                      0.000                                                 

###### 

Time trend results for all univariate meta-analyses.

  SNP               Disease            p-value cumulative   Proteus phenomenon
  ----------------- --------- -------- -------------------- --------------------
  A1166C/*AGTR1*    CKD       C vs A   0.789                NO
  CC vs AA + AC     0.501     NO                            
  AA vs CC + AC     0.432     NO                            
  ESRD              C vs A    0.017    YES                  
  CC vs AA + AC     0.000     YES                           
  AA vs CC + AC     0.783     NO                            
  IgA Nephropathy   C vs A    0.008    YES                  
  CC vs AA + AC     0.488     NO                            
  AA vs CC + AC     0.000     YES                           
  VUR               C vs A    0.000    YES                  
  A1332G/*AGTR2*    VUR       G vs A   0.000                YES

###### 

Multivariate meta-analysis for all contrasts performed for *AGTR1* (A1166C) polymorphism.

  Disease           Number of studies   Contrast   OR     95% confidence interval   
  ----------------- ------------------- ---------- ------ ------------------------- ------
  ESRD              14                  AC vs AA   1.14   0.94                      1.37
  CC vs AA          1.29                0.78       2.15                             
  CKD               6                   AC vs AA   1.17   0.73                      1.88
  CC vs AA          1.08                0.46       2.52                             
  IgA Nephropathy   5                   AC vs AA   1.01   0.81                      1.25
  CC vs AA          0.95                0.61       1.47                             
  VUR               2                   AC vs AA   1.29   0.73                      2.29
  CC vs AA          0.16                0.02       1.39                             
